Poxel Stock (OTC:PXXLF), Trade Ideas

Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

AAVXF

ADBE

ADYYF

AFGC

AHCHY

AIQUY

ALFVY

ARES

ASGN

ASGTF

ASML

ASND

ATBYF

ATEYY

ATGN

ATXI

AUPH

AXAHY

AZMTF

BABA

BKFKF

BMRPF

BOLD

BOOT

BTBIF

BURBY

BXMT

CATM

CBRE

CDAY

CGEN

CGPZF

CHNG

CHTR

CODI

CROX

CRUS

CSTL

CTRN

CWXZF

CYDY

DGDM

DIOD

DNNGY

DSDVY

DYFSF

EDPFY

EPAM

ESPR

Eaton Vance Tax-Advantaged Global Dividend

EXPGY

FBMS

FERGY

FFMR

FGBI

FICO

Stocks That Hit 52-Week Highs On Friday

Poxel SA

The former personal lawyer to Donald Trump, Michael Cohen, has pledged to stop all public commentary about the former president until after his testimony in the ongoing hush-money trial.
What Happened: On Thursday, Cohen announced on his X (formerly Twitter) account, &#8220;Despite not being the gagged defendant, out of respect for Judge Merchan and the prosecutors, I will cease posting anything about Donald on my X (formerly Twitter) account or on the Mea Culpa Podcast until after my trial testimony. See you all in a month (or more).&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Despite not being the gagged defendant, out of respect for Judge Merchan and the prosecutors, I will cease posting anything about Donald on my X (formerly Twitter) account or on the Mea Culpa Podcast until after my trial testimony. See you all in a month (or more). <a href="https://twitter.com/hashtag/TeamCohen?src=hash&amp;ref_src=twsrc%5Etfw">#TeamCohen</a> <a href="https://t.co/fzuQAffQRm">pic.twitter.com/fzuQAffQRm</a>
&mdash; Michael Cohen (@MichaelCohen212) <a href="https://twitter.com/MichaelCohen212/status/1783220136612131000?ref_src=twsrc%5Etfw">April 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Business Insider <a href="https://www.businessinsider.com/michael-cohen-trump-manhattan-merchan-hush-money-2024-4?IR=T">reported</a> that legal experts voiced concerns about Cohen&#8217;s ongoing public commentary on the case, which could potentially offer more material for Trump&#8217;s lawyers during cross-examination. Cohen&#8217;s choice to stay silent could be a strategic move to prevent jeopardizing his testimony.
Trump, who has consistently attacked Cohen&#8217;s credibility, is also being scrutinized for possibly violating Judge Juan Merchan&#8217;s gag order. Cohen&#8217;s forthcoming testimony is expected to be a significant event in the trial.
Why It Matters: Cohen is a <a href="https://www.benzinga.com/news/24/04/38240217/michael-cohen-suggests-public-will-be-surprised-by-bombshell-evidence-in-donald-trumps-hush-money-tr">key figure in the New York prosecutors</a>&#8216; accusations of falsified business records to hide hush money paid to adult film actress Stormy Daniels before the 2016 presidential election. He is also a crucial witness in Trump&#8217;s fraud trial.
See Also: <a href="https://www.benzinga.com/general/politics/24/04/38362005/donald-trump-may-soon-receive-36-million-more-djt-shares-key-milestone-ahead?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Donald Trump May Soon Receive An Additional $1.26B In DJT Shares: Key Milestone Ahead (UPDATED)</a>
It is worth noting that <a href="https://www.benzinga.com/news/24/04/38240217/michael-cohen-suggests-public-will-be-surprised-by-bombshell-evidence-in-donald-trumps-hush-money-tr">this case is moving forward</a> in contrast to Trump&#8217;s other criminal cases, which seem to be at a standstill. 
This also comes on the heels of Trump&#8217;s close allies including Boris Epshteyn, Mark Meadows, and Rudy Giuliani <a href="https://www.benzinga.com/news/24/04/38420233/trump-allies-giuliani-meadows-indicted-by-arizona-grand-jury-for-alleged-2020-election-subversion-ex">being indicted by an Arizona grand jury</a> for alleged involvement in attempts to overturn the 2020 election results.
Read Next: <a href="https://www.benzinga.com/news/24/04/38405064/anthony-scaramucci-says-nikki-haley-is-still-polling-nicely-in-pa-despite-ending-bid-against-trump-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Says Nikki Haley Is Still Polling &#8216;Nicely&#8217; In PA, Despite Ending Bid Against Trump: &#8216;And If You Are With Him: CRY&#8217;</a>
Photo by a katz on Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Politics

General

Former Trump Attorney Vows To Cease Public Criticism Of Ex-President Until Hush-Money Trial Is Over

Guidance

SPGI

S&P Global Sees FY24 Adj EPS Of $13.85 - $14.10 Vs. $14.11 Est.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $90 price target.

Price Target

Reiteration

Analyst Ratings

VKTX

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target

Second quarter&nbsp;revenue is expected to reflect approximately&nbsp;20%&nbsp;year-on-year growth and sequential growth of&nbsp;8%, with Adjusted EBITDA Margin in an expected range of&nbsp;20%&nbsp;to&nbsp;21%, or up 200 to 300 basis points year-on-year and sequentially in both cases based on the mid-point of&nbsp;second quarter&nbsp;guidance.&quot;

XPRO

Expro Group Expects Q2 Revenue To Reflect Approximately 20% Y/Y Growth And Sequential Growth Of 8%

S&P Global Raises FY24 Revenue Outlook From 5.5% - 7.5% to 6.0% - 8.0%

By <a href="https://roboforex.com/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_25042024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex</a> Analytical Department
The USD/JPY pair reached an all-time high on Thursday, touching the 155.50 level. This development comes as the Bank of Japan (BoJ) starts its two-day monetary policy meeting with widespread expectations that the interest rate will remain unchanged at zero. Investors are keenly watching for any aggressive signals from the BoJ, as further declines in the yen could prompt Tokyo to intervene in the currency market. However, any such intervention is expected to provide only a short-term respite for the yen.
The primary driver behind the yen&#39;s weakness remains the significant disparity in monetary policies between the Bank of Japan and the US Federal Reserve, particularly regarding interest rates. The current situation will likely persist if there is no shift in these policies.
Last week, BoJ Governor Kazuo Ueda indicated at the G-20 summit that the regulator might consider raising rates if the yen&#39;s weakness leads to a sustained increase in import prices. The BoJ is closely monitoring inflation trends, and should the consumer price index approach the 2% target, the bank may adopt a more decisive stance.
The yen has been on a consistent downward trajectory since 13 March this year, showing few signs of interruption.
USD/JPY technical analysis
<a href="https://www.benzinga.com/files/u117641/usdjpyh4_12.png"><img alt="" src="https://www.benzinga.com/files/u117641/usdjpyh4_12.png" style="height:716px; width:1596px" /></a>
On the H4 chart, USD/JPY found support at 153.65, and the fifth wave of growth is unfolding. The pair is expected to reach 155.85 soon. Following this, a corrective move to at least 154.60 (testing from above) is anticipated, potentially followed by further growth towards 156.56. This target represents the primary objective of the growth wave. This bullish scenario is technically supported by the MACD oscillator, whose signal line is above zero and trending upwards.
<a href="https://www.benzinga.com/files/u117641/usdjpyh1_10.png"><img alt="" src="https://www.benzinga.com/files/u117641/usdjpyh1_10.png" style="height:716px; width:1596px" /></a>
On the H1 chart, USD/JPY has established support at 154.55, with the upward structure aiming for 155.85. Currently, the growth to 155.73 has been executed. A slight retracement to 155.20 (testing from above) may occur next. After reaching this level, the likelihood of an ascent to 155.85 will be reassessed. This technical outlook is confirmed by the Stochastic oscillator, whose signal line is currently above 80, poised for a drop to around 50.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Japanese yen hits all-time low as BoJ meeting commences

Expro Group Reaffirms 2024 Guidance Of $1.6B-$1.7B Of Revenue (Est $1.652B) And $325M-$375M Of Adjusted EBITDA

Detroit-based automaker General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) on Tuesday detailed its plans for the relaunch of its autonomous driving unit Cruise, months after it paused operations owing to the involvement of one of its robotaxis in an <a href="https://www.benzinga.com/news/23/10/35052444/self-driving-cruise-car-accident-leaves-pedestrian-trapped-and-injured-in-san-francisco">accident in San Francisco</a>. 
What Happened: &#8220;We&#8217;re very excited that they&#8217;re back on the roads in Phoenix,&#8221; GM CEO Mary Barra said during the company&#8217;s first-quarter earnings call on Tuesday. Cruise is currently actively working to build regulator and customer trust, she noted. 
The company has strengthened the safety of its self-driving system and intends to demonstrate that the model works in one city before expanding to the next. Cruise accrued expenses of $400 million in the first quarter as compared to the $800 million in the quarter before. The company expects the unit&#8217;s <a href="https://www.benzinga.com/news/24/01/36862459/told-them-so-elon-musk-mocks-big-ticket-investor-who-chose-cruise-over-tesla-after-gms-self-driving">full-year expenses </a>to be around $1.7 billion. 
The company is presently exploring a few options to fund Cruise, including outside investment, Barra said. 
Why It Matters: Cruise suspended both autonomous and manual AV operations in the United States in October 2023. Earlier this month, the company <a href="https://www.benzinga.com/news/24/04/38155753/cruise-back-on-phoenix-roads-soon-gms-self-driving-unit-reportedly-gears-up-to-resume-robotaxi-testi">resumed manual driving in the city of Phoenix</a> to gather road information. 
These vehicles, Cruise then said, will be driven by humans without autonomous systems engaged. The company is looking to gradually scale up to driverless operations yet again. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/mobility" rel="noreferrer noopener">following this link</a>.
Read More: <a href="https://www.benzinga.com/news/24/04/38423295/ford-cfo-says-ev-price-cuts-bringing-down-revenue-faster-than-company-can-cut-costs-if-the-pricing-s">Ford CFO Says EV Price Cuts Bringing Down Revenue Faster Than Company Can Cut Costs; &#8216;If The Pricing Stabilizes&#8230;&#8217;</a>
Image Via Shutterstock

Tech

GM Unveils Plans For Autonomous Driving Unit Cruise Relaunch After Hiatus, Expects $1.7B In Expenses

WIIM

Southwest Airlines shares are trading lower after the company reported worse-than-expected Q1 financial results.

Earnings

Health Care

Laboratory Corporation Of America Holdings

Labcorp Expects 2024 Adjusted EPS Of $14.45-$15.35 Versus Prior Guidance Of $14.30-$15.40 And Consensus Of $14.82

First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 100 percent. This is a 86.67 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $51.069 million which missed the analyst consensus estimate of $56.690 million by 9.92 percent. This is a 27.51 percent decrease over sales of $70.453 million the same period last year.

Earnings Beats

Earnings Misses

FFWM

First Foundation Q1 2024 Adj EPS $0.02 Beats $0.01 Estimate, Sales $51.069M Miss $56.690M Estimate

Baird analyst Tristan Gerra maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Neutral and raises the price target from $125 to $175.

Baird Maintains Neutral on Texas Instruments, Raises Price Target to $175

2%&nbsp;to&nbsp;4%&nbsp;(1%&nbsp;to&nbsp;3%&nbsp;on an organic basis).

For FY24, Dover Updated Adj. EPS Outlook To $9.00-$9.15 (From $8.95-$9.15 Prior) Vs. Consensus Of $9.06; Reaffirms Revenue Growth Of 2%-4% And 1%-3% On An Organic Basis

S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) reported quarterly earnings of $4.01 per share which beat the analyst consensus estimate of $3.66 by 9.56 percent. This is a 27.3 percent increase over earnings of $3.15 per share from the same period last year. The company reported quarterly sales of $3.49 billion which beat the analyst consensus estimate of $3.42 billion by 2.08 percent. This is a 10.47 percent increase over sales of $3.16 billion the same period last year.

S&P Global Q1 Adj $4.01 Beats $3.66 Estimate, Sales $3.49B Beat $3.42B Estimate

Dividends

NDAQ

Nasdaq Increases Quarterly Dividend From $0.22 To $0.24

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported quarterly earnings of $3.68 per share which beat the analyst consensus estimate of $3.48 by 5.75 percent. This is a 6.36 percent increase over earnings of $3.46 per share from the same period last year. The company reported quarterly sales of $3.177 billion which beat the analyst consensus estimate of $3.117 billion by 1.93 percent. This is a 4.58 percent increase over sales of $3.038 billion the same period last year.

Laboratory Corp Q1 2024 Adj EPS $3.68 Beats $3.48 Estimate, Sales $3.177B Beat $3.117B Estimate

Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.10 by 110 percent. The company reported quarterly sales of $41.927 million which beat the analyst consensus estimate of $38.000 million by 10.33 percent. This is a 31.37 percent increase over sales of $31.916 million the same period last year.

ULBI

Ultralife Q1 2024 Adj EPS $0.21 Beats $0.10 Estimate, Sales $41.927M Beat $38.000M Estimate

Biotech

Large Cap

Bristol Myers Squibb Revises 2024 Adjusted EPS Guidance From $7.10-$7.40 To $0.40-$0.70 Versus Consensus Of $0.66, Reflecting The Impact Of Recent Transactions

Baird analyst Mark Marcon maintains ASGN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) with a Neutral and raises the price target from $99 to $104.

Baird Maintains Neutral on ASGN, Raises Price Target to $104

DTE Energy Reaffirms FY24 Operating EPS Of $6.54-$6.83 Vs. $6.69 Est.

Poxel S.A. reports Q1 results

Poxel S.A. reports Q2 results

PXXLF

Poxel